Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement

International Journal of Clinical Pharmacology and Therapeutics

Volumn 55, Issue 2, 2017, Pages 126-132

  Chen, Weirong ^a,b   Wu, Luhua ^a,b   Liu, Xin ^a,c   Shen, Yue ^c   Liang, Yan ^d   Zhu, Jun ^d   Tan, Huiqiong ^d   Yang, Yanmin ^d   Liu, Qun ^e   Wang, Mingsheng ^e   Liu, Lisheng ^a   Wang, Xingyu ^a,c  

^a Beijing Hypertension League Institute   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

^d FUWAI HOSPITAL   (China)

^e Beijing ShiJingShan Hospital ^*  (China)

Author keywords

Atrial fibrillation valve replacement; CYP2C9; Single nucleotide polymorphisms; VKOCR1; Warfarin dose requirements

Indexed keywords

DNA; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; CYP2C9 GENE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HEART VALVE REPLACEMENT; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL PATIENT; TREATMENT DURATION; VKORC1 GENE; ADVERSE EFFECTS; AORTIC VALVE; BLOOD CLOTTING; CHINA; COMPARATIVE STUDY; DOSE CALCULATION; DRUG EFFECTS; GENETICS; INTERNATIONAL NORMALIZED RATIO; METABOLISM; MULTIVARIATE ANALYSIS; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; STATISTICAL MODEL; STROKE; SURGERY; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; AORTIC VALVE; BLOOD COAGULATION; CHINA; CYTOCHROME P-450 CYP2C9; DRUG DOSAGE CALCULATIONS; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; STROKE; THROMBOSIS; TREATMENT OUTCOME; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 85011309003     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202494     Document Type: Article

References (31)

1. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 546S-592S. PubMed
2. Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol. 2007; 136: 26-29. CrossRef PubMed
3. Lesko LJ. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther. 2008; 84: 301-303. CrossRef PubMed
4. Lal S, Jada SR, Xiang X, Lim WT, Lee EJ, Chowbay B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin Phar macokinet. 2006; 45: 1189-1200. CrossRef PubMed
5. Walton R, Kimber M, Rockett K, Trafford C, Kwiatkowski D, Sirugo G. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat Genet. 2005; 37: 915-916, author reply 916. CrossRef PubMed
6. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther. 2005; 78: 540-550. CrossRef PubMed
7. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54: 1257-1270. CrossRef PubMed
8. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427: 537-541. CrossRef PubMed
9. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352: 2285-2293. CrossRef PubMed
10. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarintreated cohort supports genetic forecasting. Blood. 2009; 113: 784-792. CrossRef PubMed
11. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008; 358: 999-1008. CrossRef PubMed
12. Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther. 2007; 81: 742-747. CrossRef PubMed
13. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, Hou ZS, Xu S, Ma SJ, Wu M et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta. 2008; 396: 76-79. PubMed
14. Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, Heit JA. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009; 84: 1079-1094. CrossRef PubMed
15. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007; 7: 99-111. CrossRef PubMed
16. Shil AB, Strohm MP. Warfarin pharmacogenetics. N Engl J Med. 2009; 360: 2474-2475, author reply 2475. CrossRef PubMed
17. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009; 5: e1000433. CrossRef PubMed
18. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005; 105: 645-649. CrossRef PubMed
19. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005; 106: 135-140. CrossRef PubMed
20. Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, Chen YT. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics. 2009; 10: 1905-1913. CrossRef PubMed
21. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, Yap HL, Rankin SC, Khor HB, Yeo TC, Ng KS, Soong R, Goh BC. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther. 2006; 79: 197-205. CrossRef PubMed
22. Wang LS, Shang JJ, Shi SY, Zhang YQ, Lin J, Guo ZH, Wang YC, Tang J, Liu J, Liu YZ, Li Z, Tan ZR, Zhou HH, Jiang HH, Xie HT. Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage. Eur J Clin Pharmacol. 2013; 69: 1113-1120. PubMed
23. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73: 67-74. CrossRef PubMed
24. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol. 2005; 60: 418-422. CrossRef PubMed
25. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005; 14: 1745-1751. CrossRef PubMed
26. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics. 2005; 15: 687-691. Cross- Ref PubMed
27. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9- Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996; 6: 341-349. CrossRef PubMed
28. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 2010; 70: 234-240. CrossRef PubMed
29. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D. Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther. 2001; 70: 159-164. CrossRef PubMed
30. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992; 116: 901-904. CrossRef PubMed
31. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003; 3: 221-230. CrossRef PubMed